Jupiter Topco LLC Invests $793,000 in CorVel Corp. $CRVL

Jupiter Topco LLC acquired a new position in CorVel Corp. (NASDAQ:CRVL) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 12,699 shares of the business services provider’s stock, valued at approximately $793,000.

Several other large investors also recently added to or reduced their stakes in CRVL. Canada Pension Plan Investment Board bought a new position in CorVel in the second quarter worth approximately $1,082,000. Legal & General Group Plc purchased a new stake in shares of CorVel in the 2nd quarter worth $4,263,000. The Manufacturers Life Insurance Company purchased a new stake in shares of CorVel in the 2nd quarter worth $931,000. Algert Global LLC raised its holdings in CorVel by 67.0% in the 2nd quarter. Algert Global LLC now owns 383,419 shares of the business services provider’s stock worth $23,971,000 after purchasing an additional 153,877 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in CorVel during the second quarter valued at $279,000. 51.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CRVL. Weiss Ratings upgraded CorVel from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, September 1st. Wall Street Zen raised CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Insiders Place Their Bets

In other CorVel news, Director R. Jessup sold 4,023 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $70.07, for a total transaction of $281,891.61. Following the completion of the sale, the director directly owned 111,798 shares of the company’s stock, valued at $7,833,685.86. This trade represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Maxim Shishin sold 2,250 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $60.59, for a total transaction of $136,327.50. Following the sale, the insider directly owned 7,050 shares of the company’s stock, valued at approximately $427,159.50. This trade represents a 24.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,197 shares of company stock valued at $1,315,568 in the last 90 days. 39.72% of the stock is currently owned by company insiders.

CorVel Stock Performance

Shares of CorVel stock opened at $68.23 on Monday. CorVel Corp. has a fifty-two week low of $44.83 and a fifty-two week high of $93.45. The company has a market capitalization of $3.48 billion, a P/E ratio of 30.32 and a beta of 0.97. The company has a fifty day moving average of $64.25 and a 200 day moving average of $59.06.

CorVel (NASDAQ:CRVL) last announced its quarterly earnings data on Tuesday, August 4th. The business services provider reported $0.63 EPS for the quarter. The business had revenue of $259.93 million for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.72%.

CorVel Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).